Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma

NCT04204161 is registered in ClinicalTrials.gov with Shenzhen BinDeBio Ltd. as lead sponsor.

NCT NCT04204161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04204161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of CAR-T19/CAR-T22 Treatment for Children With CD19 Positive Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma
Lead sponsor
Shenzhen BinDeBio Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 8, 2019
Completion date
October 8, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell acute lymphoblastic leukemia, childhood, relapsed b-cell acute lymphoblastic leukemia, childhood, relapsed/refractory b-cell lymphoma, childhood